睿知中国医院研究地图
候选清单

即将招募胰腺癌乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer

ClinicalTrials.gov 上登记的一项胰腺癌和乳腺癌开放试验,由复旦大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07825753,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 9

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(9 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically confirmed recurrent (unresectable) or metastatic advanced pancreatic cancer or breast cancer.

    入选标准第 4 条

  3. History of myocardial infarction or symptomatic congestive heart failure (CHF) (New York Heart Association [NYHA] Class II-IV) within 6 months prior to enrollment. Patients with troponin levels above the upper limit of normal (ULN) at screening, as defined by the manufacturer, in the absence of any myocardial infarction-related symptoms, must undergo cardiology consultation prior to enrollment to rule out myocardial infarction.

    排除标准第 7 条

  4. Documented failure of standard-of-care therapy in the recurrent/metastatic setting, with receipt of at least 2 prior lines of chemotherapy. If disease recurrence occurs within 6 months after completion of (neo)adjuvant chemotherapy, the adjuvant chemotherapy regimen shall be counted as 1 line of prior chemotherapy. Additionally:

    入选标准第 6 条

    Women of childbearing potential (WOCBP) must agree to use highly effective contraceptive measures from the start of screening through 7 months after the last dose of study treatment, and must agree not to breastfeed. A negative serum pregnancy test is required within 7 days prior to the first dose of study treatment.

    入选标准第 17 条

    Participation in any other interventional clinical trial (excluding observational studies) within 4 weeks (or 5 half-lives of the investigational product, whichever is shorter) prior to the first dose of study treatment. Receipt of any of the following within the specified time windows prior to the first dose of study treatment:

    排除标准第 2 条

    Use of immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes within 2 weeks prior to the first dose of study treatment (dose >10 mg/day prednisone or equivalent dose of other corticosteroids). Nasal spray or inhaled corticosteroids are excluded from this criterion.

    排除标准第 13 条

  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

    入选标准第 2 条

  6. Hemoglobin ≥90 g/L (without transfusion within 14 days prior to screening).

    入选标准第 9 条

    Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L.

    入选标准第 10 条

    Platelet count ≥90 × 10⁹/L.

    入选标准第 11 条

    Total bilirubin ≤1.5 × upper limit of normal (ULN).

    入选标准第 12 条

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN; if hepatic metastases are present, ALT and AST ≤5 × ULN.

    入选标准第 13 条

    Serum creatinine ≤1.5 × ULN, or creatinine clearance ≥60 mL/min as calculated by the Cockcroft-Gault formula.

    入选标准第 14 条

    International normalized ratio (INR)/prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤1.5 × ULN.

    入选标准第 15 条

  7. At least 1 extracranial measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    入选标准第 7 条

  8. Presence of or history of other malignancies, with the following exceptions: cured basal cell carcinoma or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, papillary thyroid carcinoma, ductal carcinoma in situ of the breast, or any other malignancy with disease-free survival exceeding 3 years.

    排除标准第 4 条

    Active primary immunodeficiency, known human immunodeficiency virus (HIV) infection, active hepatitis B (HBsAg-positive with HBV DNA ≥500 IU/mL), or active hepatitis C infection. Among patients who are hepatitis C antibody-positive, only those with negative HCV RNA by polymerase chain reaction (PCR) are eligible for enrollment.

    排除标准第 16 条

  9. Pregnant or breastfeeding women; women of childbearing potential who are unwilling or unable to use highly effective contraceptive measures.

    排除标准第 20 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07825753,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Male or female patients aged ≥18 years and ≤75 years at the time of informed consent.
  2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  3. Life expectancy of ≥3 months, as assessed by the investigator.
  4. Histologically confirmed recurrent (unresectable) or metastatic advanced pancreatic cancer or breast cancer.
  5. Radiographic or objective evidence of disease progression during or following the last systemic therapy administered prior to the first dose of study treatment.
  6. Documented failure of standard-of-care therapy in the recurrent/metastatic setting, with receipt of at least 2 prior lines of chemotherapy. If disease recurrence occurs within 6 months after completion of (neo)adjuvant chemotherapy, the adjuvant chemotherapy regimen shall be counted as 1 line of prior chemotherapy. Additionally:
  7. At least 1 extracranial measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
  8. Adequate organ and bone marrow function, as demonstrated by the following laboratory values obtained within 14 days prior to the first dose of study treatment:
  9. Hemoglobin ≥90 g/L (without transfusion within 14 days prior to screening).
  10. Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L.
  11. Platelet count ≥90 × 10⁹/L.
  12. Total bilirubin ≤1.5 × upper limit of normal (ULN).
  13. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN; if hepatic metastases are present, ALT and AST ≤5 × ULN.
  14. Serum creatinine ≤1.5 × ULN, or creatinine clearance ≥60 mL/min as calculated by the Cockcroft-Gault formula.
  15. International normalized ratio (INR)/prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤1.5 × ULN.
  16. Left ventricular ejection fraction (LVEF) ≥50% as assessed by echocardiography or multigated acquisition (MUGA) scan; QTcF <470 ms for female patients.
  17. Women of childbearing potential (WOCBP) must agree to use highly effective contraceptive measures from the start of screening through 7 months after the last dose of study treatment, and must agree not to breastfeed. A negative serum pregnancy test is required within 7 days prior to the first dose of study treatment.
  18. Voluntary written informed consent signed prior to any study-specific procedures, with the expectation of good compliance and willingness to adhere to all protocol-specified study requirements.

排除标准:Exclusion Criteria:

  1. Known history of severe hypersensitivity to the investigational drug substance, any excipients contained in the study drug formulation, or other monoclonal antibodies/peptides.
  2. Participation in any other interventional clinical trial (excluding observational studies) within 4 weeks (or 5 half-lives of the investigational product, whichever is shorter) prior to the first dose of study treatment. Receipt of any of the following within the specified time windows prior to the first dose of study treatment:
  3. Leptomeningeal metastases or active brain parenchymal metastases. Patients with clinically stable brain parenchymal metastases may be eligible, including those with asymptomatic brain metastases that have not received prior local therapy; or patients who have previously received treatment for CNS metastases (radiotherapy or surgery), provided that imaging-confirmed disease stability has been maintained for at least 4 weeks and symptomatic treatment (including corticosteroids and mannitol) has been discontinued for more than 2 weeks.
  4. Presence of or history of other malignancies, with the following exceptions: cured basal cell carcinoma or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, papillary thyroid carcinoma, ductal carcinoma in situ of the breast, or any other malignancy with disease-free survival exceeding 3 years.
  5. Uncontrolled concurrent illness, including but not limited to: persistent or active infection, uncontrolled or clinically significant cardiovascular disease, severe chronic gastrointestinal disease associated with diarrhea, or any psychiatric illness or social situation that, in the investigator's judgment, would limit compliance with study requirements, significantly increase the risk of adverse events, or impair the ability to provide written informed consent.
  6. Uncontrolled or clinically significant cardiovascular disease, including any of the following:
  7. History of myocardial infarction or symptomatic congestive heart failure (CHF) (New York Heart Association [NYHA] Class II-IV) within 6 months prior to enrollment. Patients with troponin levels above the upper limit of normal (ULN) at screening, as defined by the manufacturer, in the absence of any myocardial infarction-related symptoms, must undergo cardiology consultation prior to enrollment to rule out myocardial infarction.
  8. Uncontrolled hypertension.
  9. Uncontrolled and/or clinically significant cardiac arrhythmias.
  10. QT interval corrected by the Fredericia method (QTcF) >470 ms for female patients, based on the mean of three 12-lead electrocardiogram (ECG) results obtained during the screening period.
  11. History of steroid-treated (non-infectious) interstitial lung disease (ILD)/pneumonitis, current ILD/pneumonitis, or suspected ILD/pneumonitis on screening imaging that cannot be ruled out.
  12. Clinically significant pulmonary comorbidities, including but not limited to: any underlying pulmonary disease (i.e., pulmonary embolism within 3 months prior to study enrollment, severe asthma, severe chronic obstructive pulmonary disease [COPD], restrictive lung disease, significant pleural effusion, etc.); any autoimmune, connective tissue, or inflammatory disease with pulmonary involvement (i.e., rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc.); and/or prior pneumonectomy (completed).
  13. Use of immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes within 2 weeks prior to the first dose of study treatment (dose >10 mg/day prednisone or equivalent dose of other corticosteroids). Nasal spray or inhaled corticosteroids are excluded from this criterion.
  14. Any active autoimmune disease or history of autoimmune disease with potential for relapse. Patients with skin conditions not requiring systemic treatment (e.g., vitiligo, psoriasis, alopecia), well-controlled type 1 diabetes mellitus on insulin therapy, or asthma that has completely resolved since childhood and requires no intervention in adulthood may be enrolled. Patients with asthma requiring bronchodilator therapy are not eligible.
  15. Uncontrolled infection requiring intravenous antibiotics, antiviral agents, or antifungal agents.
  16. Active primary immunodeficiency, known human immunodeficiency virus (HIV) infection, active hepatitis B (HBsAg-positive with HBV DNA ≥500 IU/mL), or active hepatitis C infection. Among patients who are hepatitis C antibody-positive, only those with negative HCV RNA by polymerase chain reaction (PCR) are eligible for enrollment.
  17. Unresolved toxicity from prior anti-cancer therapy, defined as toxicity not resolved to Grade ≤1 or baseline (excluding alopecia). Patients with chronic, stable Grade 2 toxicity that the investigator considers related to prior anti-cancer therapy (defined as no worsening to Grade ≥2 for at least 3 months prior to enrollment and manageable with standard treatment) may be enrolled (e.g., chemotherapy-induced neuropathy, fatigue). Residual toxicity from prior immune-oncology (IO) therapy: Grade 1 or Grade 2 endocrinopathies, which may include: (a) hypothyroidism/hyperthyroidism; (b) type 1 diabetes mellitus; (c) hyperglycemia; (d) adrenal insufficiency; (e) adrenalitis; (f) skin depigmentation (vitiligo).
  18. Imaging evidence of tumor invasion into major blood vessels, or, in the investigator's judgment, a very high likelihood of tumor invasion into major blood vessels during treatment that could result in fatal hemorrhage.
  19. Major surgical procedure, severe traumatic injury, fracture, or ulcer within 4 weeks prior to the first dose of study treatment.
  20. Pregnant or breastfeeding women; women of childbearing potential who are unwilling or unable to use highly effective contraceptive measures.
  21. Any other condition that, in the investigator's judgment, may interfere with the conduct of the study or the interpretation of study results.

引自 ClinicalTrials.gov, NCT07825753, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07825753,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07825753